Please login to the form below

Global communications during and post a worldwide pandemic: how can organisations break through the noise?

COVID-19 has understandably dominated the news agenda like no other story in a generation. But what about other disease areas that are both important and deserve public attention? How do we break through this wall, particularly as coronavirus looks set to govern the news agenda for the next few months at least, if not longer?

Zuzanna Grzeskiewicz, Account Director, Hanover

Large organisations and health-focused charities need to plan now to ensure their disease area of focus remains on the table. In many cases, plans made for 2020 need to be adapted. If we take a step back from the chaos and confusion, there are ample opportunities for our industry.

Embrace social and virtual

As the world stays at home more, in addition to holding your conferences online, highly targeted social media is key: disseminating messages to reach the right audiences at the right time, is more important than ever. We are seeing organisations which previously hesitated to use this platform starting to embrace it more, with great success.

Respond to the news agenda

During the pandemic, companies and charities need to be agile. It is worth exploring how your disease area has been affected: check-ups have been cancelled to free up health services across the globe, for example. Some charities have taken this as a chance to sensitively reiterate the importance of care in their field. In the UK, an example of this is Macmillan Cancer Support’s latest campaign.

In the pharmaceutical world, many are effectively emphasising solutions to alleviating burdens faced by health systems around the world. Examples of this include alternative therapeutic options available such as remote treatment, which has the potential to alleviate pressures on health services: a crucial concern of today’s media.

In other words, organisations need to ensure they are part of the global news agenda: not swept away by it.

Search for positivity

Positive non-coronavirus related news, we’ve found, is in high demand by the press. Organisations should consider this, and work with relevant contacts. It may not get you the front page during the height of the pandemic, but leading international outlets are made up of more than just the cover.

Looking to a post-pandemic world

What can large organisations do now to prepare to tell their story in a post-pandemic world? There will be a time when coronavirus is no longer front of mind. Organisations therefore need to plan ahead.

Today is the perfect time to craft your story; clarity in your mission, vision and values. Because in a post-pandemic world, values will be scrutinised. What did you do during the pandemic? How did you communicate this, is this aligned with your identity as a business? Did you build relationships that will help better patient outcomes? Get your story ready now and be ready to launch it as soon as the time is right.

As global communicators, we are skilled at adapting to trends and getting ahead of them. The worldwide pandemic, although a time of unprecedented uncertainty in our lifetimes, doesn’t change these fundamental principles.

13th May 2020


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

70 Gray's Inn Road
United Kingdom

Latest content on this profile

Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications
COVID-19 has changed the way we must talk about treatment for rare diseases
The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.
Hanover Communications
What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.
Hanover Communications
It's out - so what?
The European Commission’s Pharmaceutical Strategy has been published and the Commission has presented its priorities for the coming years. The focus is on patient access to affordable treatments; ensuring and boosting the competitiveness of the European pharmaceutical sector and making sure that the EU will have a strong voice on global health and pharmaceutical policy. Stakeholders now need to make sure that their voices are heard and included in upcoming proposals and, eventually, in legislation. By Jenni Kortelainen, Hanover EU
Hanover Communications
Let's be ambitious for patients and life sciences investment in Global Britain
“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.
Hanover Communications